Stockscreener 앱 받기
6.34
2.76%
-0.18
시간 외 거래:
6.35
0.010
+0.16%
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
RA Capital-linked entities receive 22,100 LENZ (LENZ) options via director grant - Stock Titan
LENZ (NASDAQ: LENZ) director awarded 22,100 stock options at $6.63 strike - Stock Titan
LENZ Therapeutics grants 22,100 options to director | LENZ Insider Trading - Stock Titan
Lenz Therapeutics shareholders elect directors and ratify auditor at annual meeting - Investing.com Australia
[8-K] LENZ Therapeutics, Inc. Reports Material Event - Stock Titan
CCCC News | C4 THERAPEUTICS INC (NASDAQ:CCCC) - ChartMill
LENZ Technical Analysis & Stock Price Forecast - Intellectia AI
Everest medicines acquires greater china rights to aceclidine presbyopia eye drop (VIZZ) - Ophthalmology Times
Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ) - Ophthalmology Times
LENZ Therapeutics adds China partner for presbyopia drug VIZZ - Yahoo Finance
Everest Medicines acquires Greater China rights for LENZ Therapeutics' presbyopia eyedrop VIZZ® - MSN
LENZ Therapeutics to Receive VIZZ Payments From Everest-Corxel Deal - marketscreener.com
LENZ Therapeutics (LENZ) Stock Price, News & Analysis - MarketBeat
LENZ Therapeutics and Everest Medicines Form Strategic Partnership for Development and Commercialization of VIZZ in Greater China - Quiver Quantitative
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ - LENZ Therapeutics
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China - The Norfolk Daily News
LENZ Therapeutics (LENZ) price target decreased by 20.47% to 39.10 - MSN
Eye drop company LENZ heads to three investor conferences in June - Stock Titan
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Earnings call transcript: LENZ Therapeutics sees growth in Q1 2026 By Investing.com - Investing.com Nigeria
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates - MSN
Users - FinancialContent
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts - Yahoo Finance
LENZ Therapeutics Q1 2026 earnings preview - MSN
Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st
Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade - Yahoo Finance
Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts - Sahm
LENZ Stock Price, Quote & Chart | LENZ THERAPEUTICS INC (NASDAQ:LENZ) - ChartMill
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - 富途牛牛
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
LENZ Therapeutics, Inc. (LENZ) reports Q1 loss, beats revenue estimates - MSN
Citi Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
LENZ Therapeutics Company Profile & Introduction - Moomoo
MSN Money - MSN
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $12 to $60 - Moomoo
Lenz Therapeutics price target raised to $31 from $29 at BofA - TipRanks
LENZ Therapeutics stock price target lowered to $38 by H.C. Wainwright - Investing.com Nigeria
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright - TipRanks
LENZ Therapeutics Q1 earnings call highlights - MSN
Lenz outlines sales force reaching 15,000 eye care professionals by quarter end as VIZZ adoption actions roll out - MSN
Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler - TipRanks
Piper Sandler cuts Lenz Therapeutics stock rating on slow sales - Investing.com
Piper Sandler cuts Lenz Therapeutics stock rating on slow sales By Investing.com - Investing.com Australia
2.60%
0.94%
자본화:
|
볼륨(24시간):